Descamps O S
Centre de Recherche Médicale de Jolimont and Department of Internal Medicine, H pital de Jolimont, Haine Saint-Paul, Belgium.
Acta Cardiol. 2000 Dec;55(6):327-33. doi: 10.2143/AC.55.6.2005763.
Familial hypercholesterolaemia (FH) is a genetic disease in which low-density lipoproteins are defectively removed from plasma as a result of mutations that impair the function either of the LDL receptor or of the apolipoprotein B. The consequences are an elevated concentration of LDL-cholesterol and the early occurrence of cardiovascular diseases. Although FH is well understood, it remains a diagnostic challenge for the clinician. Differentiating FH from other causes of hypercholesterolaemia has, however, important clinical and therapeutic implications: FH being associated with early and severe cardiovascular risk, the plasma LDL-cholesterol must be lowered as drastically and as early as possible; because FH is a dominantly inherited disorder, family members need to be screened and counseled. Prevalence, morbidity and genetic characterization of FH have never been explored in our country. Through our experience of large-scale screening of LDL-receptor and Apo B amongst suspected individuals, we are beginning to understand the molecular spectrum of FH in Belgium. Furthermore, using the large collection of clinical data accumulated amongst patients with genetically ascertained FH, we have attempted to establish specific and sensible diagnostic criteria useful and feasible in routine medical practice.
家族性高胆固醇血症(FH)是一种遗传性疾病,由于低密度脂蛋白受体或载脂蛋白B功能受损的突变,导致血浆中的低密度脂蛋白无法正常清除。其后果是低密度脂蛋白胆固醇浓度升高,心血管疾病过早发生。尽管人们对FH已经有了充分的了解,但对临床医生来说,它仍然是一个诊断难题。然而,将FH与其他高胆固醇血症病因区分开来具有重要的临床和治疗意义:由于FH与早期和严重的心血管风险相关,必须尽早尽可能大幅度地降低血浆低密度脂蛋白胆固醇水平;由于FH是一种显性遗传疾病,需要对家庭成员进行筛查和咨询。我国从未对FH的患病率、发病率和基因特征进行过研究。通过我们对疑似个体进行大规模低密度脂蛋白受体和载脂蛋白B筛查的经验,我们开始了解比利时FH的分子谱。此外,利用在基因确诊的FH患者中积累的大量临床数据,我们试图建立在常规医疗实践中有用且可行的具体合理诊断标准。